Pharmaceutical - GlaxoSmithKline, Herceptin


Current filters:


Popular Filters

BRIC countries' breast cancer market to see 8% annual growth to 2017


The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow…

GlaxoSmithKlineGlobalHerceptinMarkets & MarketingOncologyPharmaceuticalRocheTykerb

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch


US oncologists surveyed by advisory firm Decision Resources say they prescribe drugs behemoth Pfizer's…

GlaxoSmithKlineHerceptinMarkets & MarketingNorth AmericaOncologyPfizerPharmaceuticalResearchRocheTarcevaTykerbXalkori

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin


There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

NICE views breast cancer drugs from GSK and Roche too expensive


The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…


Back to top